Veradigm (NASDAQ:MDRX) Shares Gap Up - What's Next?

Key Points

• Price action: Veradigm (MDRX) stock gapped up pre-market from $4.58 to a $5.00 open and was last trading at $4.65 on very light volume (~975 shares).
• Analyst update: Wall Street Zen raised its rating on Veradigm to a "hold" in a report published March 7.
• Company facts: Veradigm has a market cap of $506.39M, a P/E of 23.25, beta 0.54, 50-day/200-day moving averages of $4.58/$4.69, and offers EHR, practice management and revenue cycle solutions to healthcare organizations.

Veradigm Inc. (NASDAQ:MDRX - Get Free Report)'s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $4.58, but opened at $5.00. Veradigm shares last traded at $4.65, with a volume of 975 shares changing hands.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Veradigm to a "hold" rating in a report on Saturday, March 7th.

Veradigm Trading Up 2.2%

The firm has a market capitalization of $506.39 million, a price-to-earnings ratio of 23.25 and a beta of 0.54. The stock's 50-day moving average is $4.58 and its 200-day moving average is $4.69.

Veradigm Company Profile

Veradigm, Inc NASDAQ: MDRX is a healthcare technology company that provides a comprehensive suite of clinical, financial and analytical solutions to medical practices, health systems and life sciences organizations. The company's offerings are designed to streamline electronic health record (EHR) workflows, optimize revenue cycle management and improve patient engagement through integrated software modules and cloud-based platforms.

Veradigm's product portfolio includes EHR and practice management systems tailored to ambulatory and specialty care settings, as well as revenue cycle management services that encompass billing, coding and claims processing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.